Patents Examined by Arthur S Leonard
  • Patent number: 10502733
    Abstract: Compositions of, methods of making, and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and at least one nonsemiconducting polymer. Compositions of, methods of making and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and non-semiconducting polymers wherein the non-semiconducting polymer comprises more than one non-semiconducting polymer such that at least one non-semiconducting polymer is functionalized for bioconjugation. The hybrid nanoparticles are polarization-sensitive and have low mass ratios with large fluorescence.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 10, 2019
    Assignee: University of Washington Through Its Center For Commercialization
    Inventors: Daniel T. Chiu, Maxwell Zeigler
  • Patent number: 10481148
    Abstract: Provided are a cell line stably expressing voltage-gated sodium channel (Nav1.5), wherein a SCN5A gene (NCBI accession no. NM_198056) encoding Nav1.5 and a puromycin selection marker are inserted into a chromosome of a host cell, and a method of measuring cardiotoxicity of a test substance comprising: (1) contacting a test substance to the cell line of claim 1; and (2) measuring magnitude of voltage-gated sodium channel (Nav1.5) in the cell line in contact with the test substance.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: November 19, 2019
    Inventors: Jin-Sung Choi, Jeong Hee Choi
  • Patent number: 10450584
    Abstract: The present invention is directed to methods and compositions comprising novel CRISPR polypeptides and polynucleotides for site-specific cleavage and nicking of nucleic acids, transcriptional control and genome editing.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: October 22, 2019
    Inventors: Rodolphe Barrangou, Alexandra E. Briner
  • Patent number: 10435453
    Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 8, 2019
    Inventors: Jonathan Bramson, Christopher W. Helsen, Galina Denisova, Rajanish Giri, Kenneth Anthony Mwawasi
  • Patent number: 10434188
    Abstract: The present invention provides fusion proteins including a hyaluronic acid-binding domain of a cartilage matrix protein and a conserved region of a growth factor protein. Certain embodiments provide nucleic nucleic acid sequences encoding a fusion protein and compositions thereof. Methods for using fusion polypeptides and nucleic acid molecules discloses herein are also provided. In certain embodiments, the fusion proteins and/or nucleic acid molecules can be used to treat a cartilage matrix protein-related condition in a subject.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 8, 2019
    Inventors: Stephen B. Trippel, Shuiliang Shi
  • Patent number: 10435709
    Abstract: A nucleic acid containing a dopamine receptor type 2-specific promoter (D2SP) is provided. In certain embodiments, the nucleic acid includes a dopamine receptor type 2-specific promoter (D2SP), wherein the D2SP does not include exon 1 of a D2 receptor gene, wherein the D2SP comprises a Kozak sequence, and wherein the D2SP includes a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1. Also provided are expression vectors, genetically modified host cells and kits that include the subject nucleic acid.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 8, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl A. Deisseroth, Charu Ramakrishnan, Kelly Zalocusky
  • Patent number: 10428303
    Abstract: Improved methods of culturing embryos in media having amounts of lactate that have not previously been recognized as beneficial for embryo development. Also, compositions, devices and kits related to the same.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 1, 2019
    Assignee: FUJIFILM Irvine Scientific, Inc.
    Inventors: Rebecca Gilbert, Hsiao-Tzu Ni, Suh-Fon Hwan
  • Patent number: 10415040
    Abstract: Provided herein are nucleic acid amphiphiles and nanostructures such as nanotubes twisted nanotapes and helical nanotapes that comprise the amphiphiles as well as methods to deliver therapeutic agents with the nanostructures.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: September 17, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Efrosini Kokkoli, Timothy R. Pearce, Huihui Kuang
  • Patent number: 10400217
    Abstract: The present invention relates to an immortalized cell, an immortalized cell line comprising said immortalized cell, a cell culture comprising the immortalized cell or cell line, and a method for the production of an immortalized cell.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: September 3, 2019
    Inventor: Dorothea Alexander-Friedrich
  • Patent number: 10392622
    Abstract: A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mitchell Lewis, Jean Bennett, Luk Vandenberghe, Matthew Sochor, Theodore G. Drivas
  • Patent number: 10392446
    Abstract: The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 27, 2019
    Inventor: Matthias Stephan
  • Patent number: 10391126
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 27, 2019
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • Patent number: 10385314
    Abstract: A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating a population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 20, 2019
    Inventors: Chaya Brodie, Shlomit Brodie
  • Patent number: 10375936
    Abstract: Methods of producing non-human animal models of corneal angiogenesis and corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal angiogenesis and corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal angiogenesis and corneal ectatic diseases.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: August 13, 2019
    Inventor: Arturo Solis Herrera
  • Patent number: 10337016
    Abstract: The present disclosure provides a pharmaceutical composition for treating cancer comprising an RNA oligonucleotide having a particular sequence and structure. Specifically, when a cell line is treated with an RNA oligonucleotide having specific sequence and helical bend structure according to the present disclosure, the expression of ISG56 is increased and apoptosis of cancer cells is induced. Thus, a composition comprising the RNA oligonucleotide can be used as an anticancer agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: July 2, 2019
    Inventors: Byong-Seok Choi, Suk-Jo Kang, Janghyun Lee, Ji Youn Min, Dongmin Chun, Si-Eun Sung
  • Patent number: 10335491
    Abstract: This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: July 2, 2019
    Assignees: The Regents of the University of California, National Institutes of Health (NIH)
    Inventors: Hsian-Rong Tseng, Hao Wang, Kuan-Ju Chen
  • Patent number: 10323077
    Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: June 18, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta
    Inventors: H. Trent Spencer, Christopher B. Doering, Brantley R. Herrin, Max Dale Cooper
  • Patent number: 10307487
    Abstract: Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 4, 2019
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital
    Inventors: Ulrich H. von Andrian, Aude Thiriot, Omid Farokhzad, Jinjun Shi
  • Patent number: 10300148
    Abstract: Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mRNA nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid DNA itself but in the form of mRNA, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid DNA via rolling circle transcription (RCT), thereby providing a simple and economical process for gene delivery. The present invention is also concerned with such mRNA nanoparticles.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 28, 2019
    Inventors: Jong-Bum Lee, Hye-Jin Kim
  • Patent number: 10286073
    Abstract: This disclosure describes a composition and method of magnetic nanoparticles (MNP) that are bound to a baculovirus (BV). The MNP-BV can be systemically administered to a patient, and a strong magnetic field applied to the target tissue, thus allowing uptake and expression only in the target tissue. Off-target effects are not seen because the MNP-BC is inactivated by the complement system outside of the magnetic field.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 14, 2019
    Assignee: ILISA TECH, INC.
    Inventors: Haibao Zhu, Sheng Tong, Gang Bao